ADC Payloads Development

ADC Payloads Development

With a Ph.D.-level research team and years of experience in ADC development and production, BOC Sciences's ADC manufacturing platform will provide a variety of payloads for your ADC projects, driving advances in clinical trials. Antibodies-Drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves tumor-specific antibodies, linkers and cytotoxic payloads.

The payload in the ADC is a highly efficient cytotoxin that plays a role in the key cellular processes required for survival. Some payloads work by destroying the structure of DNA. For example, Calicheamicins is an effective anti-tumor antibiotic. In addition to the previously mentioned payloads, new chemical or biochemical entities are also used as payloads, which trigger specific downstream processes and cause cell damage, including drug carriers, toxic proteins, toxic enzymes, and small molecular inhibitors for other key cellular pathways. BOC Sciences has a list of potent cytotoxic payloads and can create a series of ADCs with different payloads for customers to screen. It is also possible to provide customers with a payload linker that enables them to engage on their own. The payloads that BOC Sciences can produce include:

Microtubule Inhibitors

  • Monomethyl Auristatin E (MMAE)
  • Monomethyl auristatin F (MMAF)
  • Mertansine (DM-1)
  • Maytansinoid (DM-4)
  • Dolastatin-10

DNA Intercalators

  • Pyrrolobenzodiazepines (PBDs)
  • Doxorubicin
  • Deruxtecan
  • Duocarmycin

DNA cleavers

  • Calicheamicin
  • N-Acetyl-Calicheamicin

RNA polymerase inhibitor

  • α-amanitin
  • β-Amanitin

The services that BOC Sciences can provide include

Our advantages

  • True loyalty and partnership
  • Skilled chemistry team
  • Fully equipped analytical support
  • High quality, low cost products
  • Milligram to gram lab scale
  • Kilogram GMP production
  • Advanced technology and methods
  • Comprehensive analysis of biopharmaceutical services

R&D Labs

ADC Payloads Development


  1. Martin, al. Antibody-drug conjugates: design and development for therapy and imaging in and beyond cancer, labex mabimprove industrial workshop. MAbs. 2017; 10(2):210-221.
  2. Paul J Carter, & Peter D Senter. Antibody-drug conjugates in cancer therapy. Annual Review of Medicine.2012; 14(3):154-169.
* Only for research. Not suitable for any diagnostic or therapeutic use.

Get in Touch

Verification code
Inquiry Basket